News

RALEIGH, N.C.; May 19, 2022 – Veranex — the only global, tech-enabled product development services provider focused on the medical technology industry — today announced strategic partnerships with Accelmed Partners II and Lauxera Capital Partners. Accelmed and Lauxera...

Veranex expands global capabilities for human-centered design, innovation, and strategy RALEIGH, N.C.; Dec. 7, 2021 – Veranex, the only global, tech-enabled product development services provider focused on the medical technology industry, today announced its latest...

RALEIGH, N.C.; Oct. 12, 2021 – Veranex, the first concept-to-commercialization global service provider dedicated to the MedTech industry, today announced the acquisition of IMMR, a leading preclinical science organization that provides preclinical research, pathology...

RALEIGH, N.C.; August 3, 2021 – Veranex the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical...

RALEIGH, N.C.; June 16, 2021 – Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners, the Veranex platform is...

PRINCETON, N.J., April 13, 2021 — Quartesian, a multinational clinical research organization (CRO) serving the biopharmaceutical and medical device industries, today announced a multiyear agreement with a leading portfolio medical technology company. Under the...

PRINCETON, N.J., June 16, 2020 /PRNewswire/ — Quartesian, a multinational clinical research organization (CRO) serving the biopharmaceutical and medical device industries, today announced a new partnership with Amyndas Pharmaceuticals for their Phase 2 clinical study...

Prediction: In 10 years, clinical trials will be nearly paperless. And clinical trial historians will note that the coronavirus pandemic was the tipping point. Every study has been affected. Sponsors are delaying or extending existing trials. They’re postponing new...